Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, TMTT, Surgical & IHFM | September 11, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 11, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,926 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Tax withholding · Disposed 398 · Balance 43,926 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2023 Filed Sep 6, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,500 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-23-008737 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 8,500 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,500 | $76.07 | $646,609.45 |
DisclosureSEC source: 0001225208-23-008737 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,950 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.83 to $76.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,500 | $59.26 | $503,681.95 |
DisclosureSEC source: 0001225208-23-008737 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. Read SEC document |
| August 29, 2023 Filed Aug 29, 2023 21:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,500 | $76.69 | $115,040.40 |
DisclosureSEC source: 0001225208-23-008545 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,950 F1 · price: This transaction was executed in multiple trades at prices ranging from $76.690 to $76.701. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 8,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 49,900 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,900 Underlying: Common Stock · 49,900 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 6,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005914 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,450 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 967 | $88.74 | $85,811.58 |
DisclosureSEC source: 0001225208-23-005619 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,975 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 3,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005619 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 937 Underlying: Common Stock · 3,413 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,822 | $88.74 | $161,684.28 |
DisclosureSEC source: 0001225208-23-005619 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,942 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005619 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2023 Filed May 5, 2023 01:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 279 | $88.10 | $24,579.90 |
DisclosureSEC source: 0001225208-23-005431 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,351 Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 281 | $87.81 | $24,674.61 |
DisclosureSEC source: 0001225208-23-005431 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,630 Read SEC document |
| March 15, 2023 Filed Mar 15, 2023 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,435 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-003978 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,435 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 15, 2023 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,435 | $77.47 | $343,562.60 |
DisclosureSEC source: 0001225208-23-003978 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.20 to $77.67 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2023 Filed Mar 15, 2023 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,435 | $45.28 | $200,802.16 |
DisclosureSEC source: 0001225208-23-003978 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002043 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,435 Underlying: Common Stock · 4,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $76.01 | $304,040.00 |
DisclosureSEC source: 0001225208-23-002043 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| February 15, 2023 Filed Feb 15, 2023 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $45.28 | $181,106.80 |
DisclosureSEC source: 0001225208-23-002043 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-000678 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,435 Underlying: Common Stock · 4,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $78.00 | $312,000.00 |
DisclosureSEC source: 0001225208-23-000678 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| January 17, 2023 Filed Jan 17, 2023 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $45.28 | $181,106.80 |
DisclosureSEC source: 0001225208-23-000678 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-22-012850 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,435 Underlying: Common Stock · 4,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $74.80 | $299,200.00 |
DisclosureSEC source: 0001225208-22-012850 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| December 15, 2022 Filed Dec 15, 2022 23:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $45.28 | $181,106.80 |
DisclosureSEC source: 0001225208-22-012850 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-22-011690 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,435 Underlying: Common Stock · 4,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $74.18 | $296,720.00 |
DisclosureSEC source: 0001225208-22-011690 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $45.28 | $181,106.80 |
DisclosureSEC source: 0001225208-22-011690 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-22-010969 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,435 Underlying: Common Stock · 4,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $84.77 | $339,080.00 |
DisclosureSEC source: 0001225208-22-010969 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $45.28 | $181,106.80 |
DisclosureSEC source: 0001225208-22-010969 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2022. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $102.49 | $102,490.00 |
DisclosureSEC source: 0001225208-22-009141 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,911 Read SEC document |
| May 26, 2022 Filed May 27, 2022 00:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,000 | $98.31 | $98,311.80 |
DisclosureSEC source: 0001225208-22-007410 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,911 F1 · price: This transaction was executed in multiple trades at prices ranging from $98.295 to $98.370. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2022 Filed May 18, 2022 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,644 | $95.93 | $157,708.92 |
DisclosureSEC source: 0001225208-22-007135 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,911 Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 8,531 | $100.52 | $857,536.12 |
DisclosureSEC source: 0001225208-22-006813 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,968 Underlying: Common Stock · 8,531 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,469 | $100.52 | $449,223.88 |
DisclosureSEC source: 0001225208-22-006813 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,555 Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006813 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 305 | $100.52 | $30,658.60 |
DisclosureSEC source: 0001225208-22-006813 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,493 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 279 | $105.93 | $29,554.47 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,798 Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 4,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,075 Underlying: Common Stock · 4,075 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 26,400 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,077 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 24,000 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-21-009384 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,435 Underlying: Common Stock · 24,000 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 24,000 | $99.96 | $2,398,989.60 |
DisclosureSEC source: 0001225208-21-009384 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,827 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $99.58 to $100.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 01:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 24,000 | $45.28 | $1,086,640.80 |
DisclosureSEC source: 0001225208-21-009384 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,146 | $89.49 | $102,555.54 |
DisclosureSEC source: 0001225208-21-008303 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,827 Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 304 | $91.75 | $27,892.00 |
DisclosureSEC source: 0001225208-21-007972 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,973 Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 4,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007704 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,025 Underlying: Common Stock · 4,025 shares Expires 2028-05-03 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 28,000 | $0.00 Strike: $93.31 | $0.00 |
DisclosureSEC source: 0001225208-21-007704 · doc4.xml · derivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007704 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,277 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.